Q32 Bio (QTTB) Stock Forecast & Price Target

$3.59 +0.25 (+7.49%)

(As of 12/20/2024 05:40 PM ET)

Q32 Bio - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
4

Buy
4

Based on 8 Wall Street analysts who have issued ratings for Q32 Bio in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 4 have given a hold rating, and 4 have given a buy rating for QTTB.

Consensus Price Target

$29.86
731.68% Upside

According to the 8 analysts' twelve-month price targets for Q32 Bio, the average price target is $29.86. The highest price target for QTTB is $100.00, while the lowest price target for QTTB is $9.00. The average price target represents a forecasted upside of 731.68% from the current price of $3.59.

Get the Latest News and Ratings for QTTB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Q32 Bio and its competitors.

QTTB Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	N/A
Buy	4 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	N/A
Hold	4 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$29.86	$72.33	$68.80	N/A
Forecasted Upside	731.68% Upside	167.50% Upside	40.47% Upside	N/A
Consensus Rating	Moderate Buy	Buy	Buy	N/A

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

QTTB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

QTTB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Q32 Bio Stock vs. The Competition

Type	Q32 Bio	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	731.68% Upside	25,828.59% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent QTTB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/12/2024	BMO Capital Markets 4 of 5 stars	E. Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$64.00 ➝ $22.00	+369.08%
12/11/2024	Leerink Partnrs 5 of 5 stars	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
12/11/2024	Guggenheim 2 of 5 stars	Y. Suneja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/11/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$80.00 ➝ $20.00	-18.07%
12/11/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Strong-Buy ➝ Outperform	$90.00 ➝ $22.00	-9.87%
12/11/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$68.00 ➝ $9.00	-63.13%
12/11/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$95.00 ➝ $16.00	-34.45%
12/11/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$85.00 ➝ $20.00	-18.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:50 PM ET.

QTTB Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Q32 Bio is $29.86, with a high forecast of $100.00 and a low forecast of $9.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Q32 Bio in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" QTTB shares.
: According to analysts, Q32 Bio's stock has a predicted upside of 731.68% based on their 12-month stock forecasts.
: Over the previous 90 days, Q32 Bio's stock had 2 downgrades by analysts.
: Q32 Bio has been rated by research analysts at BMO Capital Markets, Guggenheim, Leerink Partners, Leerink Partnrs, Oppenheimer, Piper Sandler, Raymond James, and Wells Fargo & Company in the past 90 days.
: Analysts like Q32 Bio less than other "medical" companies. The consensus rating score for Q32 Bio is 2.50 while the average consensus rating score for "medical" companies is 2.81. Learn more on how QTTB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NASDAQ:QTTB) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Stock Forecast & Price Target